AMRI’s Burlington, MA site has received approval to expand its current U.S. Drug Enforcement Administration (DEA) registration to handle Schedule 2 and 2N controlled substances. The Burlington site offers cGMP aseptic formulation and filling to support preclinical through commercial scale production of liquid-filled and lyophilized parenterals. The addition of Schedule 2 compounds allows Burlington to perform controlled substance work for customers, both in the lab and on the engineering/product...